Mechanism of action of an antibacterial compound : impact on the bacterial envelop integrityBackground of in vitro-MOA alteration of bacterial envelop • The mechanism of action of antibiotics varies as they damage pathogens in several ways. Fig. Mech
In vitro/ex vivo testing Antibacterial and antifungal
Background of in vitro-MOA alteration of bacterial envelop
• The mechanism of action of antibiotics varies as they damage pathogens in several ways.
Fig. Mechanisms of antibiotics actions (Microbiology 12th Std)
• The development of antimicrobial resistance toward agents that operate at the envelop level is expected to be less significant than agents that must be internalized to exert their toxic effects. By not having to enter a bacterial cell to destroy it, a therapeutic agent circumvents two of the common mechanisms of resistance, i.e., efflux mechanisms and enzymatic degradation within the cell.
Objectives of the model
• To develop an in vitro mechanistic model to address the mechanism of action of drugs in development.
• To determine whether a drug in development physically alters the bacterial envelop.
Our approach at Vibiosphen
• NPN is a dye that displays a weak fluorescence in aqueous environment vs strong fluorescence in non polar or hydrophobic environment.
• PI is a dye that shows a strong fluorescence when bound to DNA. It does not enter into living cells.
• Colistin (= polymyxin) targets outer membrane (LPS).
• Meropenem (= carbapenem) bind to Penicillin Binding Proteins and inhibits bacterial cell wall synthesis like other β-lactam antibiotics.
• Acinetobacter baumannii was incubated with either fluorescent dye and either colistin or meropenem.
Outcomes of in vitro-MOA alteration of bacterial envelop
Fig. Kinetics of fluorescence development
• This experimental approach can contribute to discovering the mechanism of action a new antibacterial drug, i.e. the putative disruption of bacterial envelop function.
Why Choose Vibiosphen?
• Proven expertise in preclinical research
• Flexible and customized study designs adapted to sponsor requirements (see downloads available as example)
• Advanced facilities to ensure reliable and reproducible results (BSL2 and BSL3)
• Strong collaborations with pharmaceutical companies, biotech firms, and academic partners
Vibiosphen combines scientific excellence with industry know-how to deliver actionable preclinical data that drive innovation in infectious disease therapeutics.
Contact Us
If you are developing new treatments or vaccines, Vibiosphen can help accelerate your research.
Contact us today to discuss your project and explore how our Pharmacokinetics models can support your development strategy. We will be pleased to facilitate your project by providing a customized study design to your project objectives.